Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study

TY - JOUR

T1 - Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus

T2 - a nested case-control study

AU - Knudsen, Andreas

AU - Møller, Holger Jon

AU - Katzenstein, Terese L

AU - Gerstoft, Jan

AU - Obel, Niels

AU - Kronborg, Gitte

AU - Benfield, Thomas

AU - Kjaer, Andreas

AU - Lebech, Anne-Mette

PY - 2013/5/21

Y1 - 2013/5/21

N2 - BACKGROUND: Soluble CD163 (sCD163) has been associated with arterial inflammation and non-calcified plaques in human immunodeficiency virus (HIV)-infected individuals and has therefore been suggested as a predictive biomarker of myocardial infarction (MI).METHODS: We conducted a nested case-control study of 55 cases with first-time MI and 182 controls matched for age, duration of antiretroviral therapy (ART), gender, smoking, and no known cardiovascular disease. All patients had four available plasma samples, 1: Before initiation of antiretroviral therapy (ART), 2: Three months after ART, 3: One year before the case's MI, and 4: The last sample available before the case's MI. We used conditional logistic regression to estimate the association of sCD163 with first-time MI.RESULTS: The two groups had similar HIV-parameters and cardiovascular risk factors were equally distributed. There was no significant association between sCD163 and MI neither in samples obtained one year before (OR 1.05, CI 95% 0.85 - 1.29, p = 0.66) nor two months before (OR 1.20, CI 95% 0.98-1.47 p = 0.08).CONCLUSION: sCD163 did not prove to be a useful biomarker for prediction of first-time MI in a HIV-infected population.

AB - BACKGROUND: Soluble CD163 (sCD163) has been associated with arterial inflammation and non-calcified plaques in human immunodeficiency virus (HIV)-infected individuals and has therefore been suggested as a predictive biomarker of myocardial infarction (MI).METHODS: We conducted a nested case-control study of 55 cases with first-time MI and 182 controls matched for age, duration of antiretroviral therapy (ART), gender, smoking, and no known cardiovascular disease. All patients had four available plasma samples, 1: Before initiation of antiretroviral therapy (ART), 2: Three months after ART, 3: One year before the case's MI, and 4: The last sample available before the case's MI. We used conditional logistic regression to estimate the association of sCD163 with first-time MI.RESULTS: The two groups had similar HIV-parameters and cardiovascular risk factors were equally distributed. There was no significant association between sCD163 and MI neither in samples obtained one year before (OR 1.05, CI 95% 0.85 - 1.29, p = 0.66) nor two months before (OR 1.20, CI 95% 0.98-1.47 p = 0.08).CONCLUSION: sCD163 did not prove to be a useful biomarker for prediction of first-time MI in a HIV-infected population.

U2 - 10.1186/1471-2334-13-230

DO - 10.1186/1471-2334-13-230

M3 - Journal article

C2 - 23692821

SN - 1471-2334

VL - 13

SP - 230

JO - B M C Infectious Diseases

JF - B M C Infectious Diseases

ER -